| Jul 9 |
European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer
|
| Jul 3 |
IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod
|
| Jul 2 |
FDA grants marketing authorisation for IceCure’s XSense Cryoablation System
|
| Jul 1 |
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes
|
| Jun 24 |
We're Keeping An Eye On IceCure Medical's (NASDAQ:ICCM) Cash Burn Rate
|
| Jun 18 |
IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024
|
| Jun 12 |
Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function
|
| Jun 4 |
IceCure Medical (ICCM) Moves to Buy: Rationale Behind the Upgrade
|
| Jun 4 |
FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan
|
| May 28 |
IceCure Medical Ltd (ICCM) Q1 2024 Earnings Call Transcript
|
